Loading
Xenograft Model Antitumor Assays / Spindle Assembly Checkpoint / Cell Line, Tumor · unknown
Cancer Biology & Therapy · June 22, 2026
Early or partial results. Treat as a signal, not a conclusion.
This preclinical study demonstrates that KIF18A inhibitor AM-1882 prevents osteosarcoma growth in cell lines and mouse xenografts by activating spindle assembly checkpoint signaling. The inhibitor showed anti-tumor efficacy without apparent toxicity compared to chemotherapeutic drugs in the mouse model.
Preclinical cell-line and xenograft study. Two whole-genome-doubling clones derived from near-diploid SJSA1 osteosarcoma cell line, plus U2OS and MG63 osteosarcoma cell lines. Intervention: KIF18A knockout or KIF18A inhibitor AM-1882. Compared with: Parental SJSA1 cells, chemotherapeutic drugs (xenograft toxicity comparison).
KIF18A depletion significantly reduced cell viability, survival, and proliferation in whole-genome-doubling SPT cells but not in parental SJSA1 cells AM-1882 showed potent anti-cancer activity in SPT, U2OS, and MG63 osteosarcoma cell lines In mouse xenograft model, AM-1882 apparently prevented tumor growth without toxicity compared to chemotherapeutic drugs
In mouse xenograft model, AM-1882 apparently prevented tumor growth without toxicity compared to chemotherapeutic drugs
KIF18A represents a potential therapeutic target for osteosarcoma exploiting chromosomal instability, though human trial data are needed. The favorable preclinical safety profile of AM-1882 compared to existing chemotherapy warrants clinical investigation.
Preclinical cell-line and xenograft data showing anti-tumor activity of a KIF18A inhibitor in osteosarcoma models without human trial evidence.
As stated by the source record.
KIF18A represents a potential therapeutic target for osteosarcoma exploiting chromosomal instability, though human trial data are needed. The favorable preclinical safety profile of AM-1882 compared to existing chemotherapy warrants clinical investigation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background. Osteosarcoma survival rates have not improved significantly in decades, as complex gene mutations and intratumoral heterogeneity hinder new therapy development. To exploit the widespread chromosomal instability in osteosarcoma, we investigated targeting the essential mitotic motor protein KIF18A.Materials. Two whole-genome-doubling clones derived from the near-diploid SJSA1 osteosarcoma cell line were used to evaluate sensitivity to KIF18A knockout or pharmacological inhibition. The traditional osteosarcoma cell lines U2OS and MG63 were included in the study of the KIF18A inhibitor at both the cellular and xenograft (nude mice) levels.Results. Depletion of KIF18A significantly reduced cell viability, survival, and proliferation in the SPT cell, but not in the parental SJSA1 cell. Loss of KIF18A expression led to aberrant spindle assembly and mitotic delay through the activation of spindle assembly checkpoint (SAC) signaling. Therefore, the deficiency of SAC rescued the SPT cell growth. We then tested one of the latest KIF18A inhibitors, AM-1882, in SPT, U2OS, and MG63 cells. It showed potent anti-cancer activity and disruption of spindle assembly activity, just like the KIF18A knockout. In the mouse xenograft model, AM-1882 also apparently prevented tumor growth and, notably, did not show any toxicity when compared with chemotherapeutic drugs.Conclusion. Overall, our study demonstrated that KIF18A is a promising therapeutic target in osteosarcoma. The novel inhibitor AM-1882 offers exceptional anti-tumor efficacy paired with a favorable, low-toxicity safety profile.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.